A single event stood out in everyone’s mind when Ophthalmology Times asked experts to think back on the year in glaucoma surgery: the July 29 approval by the U.S. Food and Drug Administration (FDA) of the CyPass Micro-Stent.
Research. Industry. Philanthropy. These three facets—each with a unique purpose—will come together for the 2017 installment of the annual Glaucoma Research Foundation (GRF) Glaucoma 360 meeting. The three-day event will occur Feb. 2 to 4, 2016.
As your patients celebrate another birthday milestone, they are again back in your chair wondering why their reading glasses mysteriously disappear when they are out exploring life or why their arms are not as long as they used to be.
Recently, I received a progress note from a glaucoma surgeon concerning a patient whom he and I share. The patient is a 58-year-old African-American female with a longstanding history of primary open-angle glaucoma.
The number of patients with glaucoma will rise dramatically in the future because of growth in both the size of the aged population and in demographic groups at high-risk for the disease. Ophthalmology, however, is not equipped to handle the increasing demand for services considering workforce projections and current models of care.